Honoring the life and spirit of your loved one.

The Neuroendocrine Tumor Research Foundation (NETRF) offers information and education to those with neuroendocrine tumors. NETRF is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) in the search for a cure. 

How we work to end NETs

Dedicated to Curing Neuroendocrine TUMORS

Million in NET research funding

of every dollar spent in 2021 supported research and education.

Ongoing studies in 10 countries


From Education to Experience: How one family’s NET experience led to better educational resources for NET patients and families.

“In 2012, my husband was diagnosed with a neuroendocrine tumor (NET) cancer. At that time, there was little information and few treatment options,” said Suzanne Ludlow, NETRF Board Member and generous benefactor of NETRF’s second edition of “Neuroendocrine Cancer: A Guide for Patients and Families.”  Suzanne lost her beloved husband Vincent in 2017, but she’s honoring his life while supporting other patients and families navigating NETs as a new member of the NETRF Board of Trustees. Read more about Suzanne and Vincent’s story here. 

NETRF-funded Research Sets the Stage for Study Exploring Use of Terbium-161 in NETs

A new clinical trial being conducted at a single center in Switzerland aims to explore a therapy using a novel somatostatin receptor subtype 2 antagonist labelled with Terbium-161 (161Tb-DOTA-LM3). The study is sponsored by University Hospital, Basel, in collaboration with the Swiss National Science Foundation and the Paul Sherrer Institute and builds upon research funded by NETRF.

Study Focuses on Matching Patients with Rare Cancers and Cancer of Unknown Primary to Targeted Treatments

A patient advocacy-led clinical research study aims to determine if patients who have rare tumors can benefit from matched molecular therapy based on the results of their genomic profiling. Patients with neuroendocrine tumors and unknown primaries may be eligible for this study. Sponsored by the TargetCancer Foundation, in collaboration with Foundation Medicine Inc., the TCF-001 TRACK (Target Rare Cancer Knowledge) Study uses next-generation sequencing to develop a comprehensive genomic profile of each participant’s tumor as well as their plasma circulating cell-free DNA (blood).


Thank you for Sparking Hope in Neuroendocrine Tumor Research.

You helped us reach our $10 million goal. Learn how your gift is helping to spark NET research.

Get Involved

You can support a brighter future. Make a gift. Host an event. Or volunteer to help us advance our understanding of neuroendocrine tumors.

Join Our Mailing List

Learn about neuroendocrine tumor tests, treatments, and research. Find out about educational and inspirational events in the NET community.

NET Events

NETRF hosts free patient and caregiver neuroendocrine tumor conferences to educate and empower individuals to be part of their care planning and live their best life.

View events page

Next upcoming event:

Know Your NETs Virtual Conference
Saturday, October 10
9 am – 1 pm ET

Register Now